RxDoctor Payments Data

Jack Finch, MD

Family Medicine · Redding, CANPI 1629168091

Payments from drug & device makers

$18,593in general payments, 2019–2025

Across 898 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$3K
  • Boehringer Ingelheim$2K
  • GSK$2K
  • Pfizer$1K
  • Novo Nordisk$1K
  • plus $8K from 32 others

What the payments were for

  • Food & beverage$18,593100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,593 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$191,506
Medicare patients
388
Services billed
2,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$99,923
EliquisApixaban68$97,811
JardianceEmpagliflozin53$67,755
FarxigaDapagliflozin Propanediol49$59,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$58,600
MounjaroTirzepatide36$43,889
VraylarCariprazine Hcl19$26,664
Repatha SureclickEvolocumab20$21,398
TrintellixVortioxetine Hydrobromide13$16,615
MyrbetriqMirabegron12$14,745
EntrestoSacubitril/Valsartan16$13,611
Breo ElliptaFluticasone/Vilanterol14$8,123
Metoprolol Succinate274$5,090
Tolterodine Tartrate ErTolterodine Tartrate24$4,371
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$3,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,040$99,923101 claims
PfizerEliquis$1,226$97,81168 claims
Boehringer IngelheimJardiance$1,839$67,75553 claims
GSKTrelegy Ellipta, Breo Ellipta$1,598$66,72366 claims
AstraZenecaFarxiga$2,712$59,84749 claims
Lilly USA, LLCMounjaro$858$43,88936 claims
AbbVieVraylar$2,540$26,66419 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$48$16,61513 claims
Astellas Pharma US IncMyrbetriq$200$14,74512 claims
NovartisEntresto$55$13,61116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →